FDA bars Chinese seafood companies from doing business in US after disturbing discovery found in imported clams — here's what it found
The U.S. Food and Drug Administration in February announced that eight Chinese seafood companies were added to its Import Alert list. The action followed the discovery of concerning levels of per- and polyfluoroalkyl substances in imported clams. The affected clams contain alarming levels of the toxic PFAS.
The FDA issued a warning to the barred seafood companies. Any attempt to enter the U.S. will lead to automatic detention at the border, without any physical inspection. This helps ensure that the contaminated seafood doesn't make it to supermarkets.
Known as "forever chemicals," PFAS are found in many industrial and everyday products. However, their presence in food and the environment can lead to severe health problems. Elevated exposure to certain PFAS has been linked to cancer, liver damage, pre-eclampsia, and high blood pressure, per the FDA.
Polluted water is the culprit for clam contamination. The National Library of Medicine reported that shellfish has the highest PFAS level. Chemical concentrations in clams, mussels, and crabs are higher than PFAS found in fish, beef, and pork. This can negatively impact regions and communities that rely on the seafood industry to boost local economies.
This isn't the first time food imports have been subject to review. Produce imported into the United Kingdom has been found with harmful pesticides not approved for use by British farmers.
The Import Alert helps ensure that consumers can trust the food they buy and won't have to make a trip to the hospital. Other rules, such as banning fisheries that don't meet U.S. bycatch standards, make trade agreements more ethical and long-lasting.
Consumers can also be proactive in lowering their PFAS exposure by staying informed about food safety alerts from reputable agencies and making smart grocery choices. Proper food preparation is also important — washing apples, for instance, doesn't fully remove pesticide residue on their skin.
Do you worry about having toxic forever chemicals in your home?
Majorly
Sometimes
Not really
I don't know enough about them
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
26 minutes ago
- Chicago Tribune
Jim Taylor: What my wife's experience with Alzheimer's has taught me
After several unexplained memory slips, there came a day when my wife, Geri, didn't recognize her own face in the mirror. That's when we knew it was time for her to get checked out. It was 2012, and Alzheimer's was a feared diagnosis. At the time, billions of dollars of investments into research and development had failed to produce treatments that could prevent, slow or cure the disease. Getting a definitive diagnosis would be extremely difficult, but the alternative was living with years of the landscape for Alzheimer's diagnosis and treatment has taken a great leap forward. It is increasingly possible to manage the disease and live a fulfilling life. We have reached a historic moment with the FDA's approval of the first blood biomarker tests for Alzheimer's. This long-awaited breakthrough means physicians can now detect early signs of Alzheimer's — which accounts for 70% of all cases of dementia — using a simple blood test that can be done during a regular check-up with your PET scans remain important for confirming a diagnosis, they are only available at specialized centers, typically in urban medical centers, and they are expensive. Blood biomarker tests now offer an easy first step in the diagnostic journey. They provide fast answers for people experiencing memory problems and can even spot early signs of cognitive decline years before symptoms appear. Without these tests, most people have a long, challenging path to wife Geri's path to diagnosis was anything but simple. In 2012, a neurologist confirmed she had mild cognitive impairment, a common precursor to Alzheimer's. It was a life-altering event. Over the next few years, we knew we had to dig deeper into the cause of her condition, to uncover any potential medical options. Eventually we found a clinical trial for an experimental Alzheimer's drug, and she received a PET scan to determine whether she qualified for the trial. Her brain scan detected amyloid plaque, the telltale sign of Alzheimer's. The diagnosis was difficult to face, but it meant we didn't have to struggle with uncertainty. We could act.I understand the fear that surrounds an Alzheimer's diagnosis, but catching it early helps. Changes in the brain begin years before memory problems become noticeable. The earlier the diagnosis, the more options people have. Research shows that anti-amyloid therapies are more effective when administered earlier: In one clinical trial, patients with early Alzheimer's showed 35% slowing of cognitive decline, compared with those on the placebo. These treatments can help people maintain their independence longer and make the most of their lucid was fortunate to participate in a clinical trial that significantly slowed her disease progression. The seven-year trial period was a game-changer for us. The regular infusions were a source of hope as we saw her benefit from the medication. This precious time allowed Geri to develop coping strategies to manage her disease. Together, we traveled across the country giving talks about living with Alzheimer's disease, and Geri needed very little assistance. We cherished this time together — years made possible because we sought answers early. Following the FDA's landmark approval of blood biomarker tests, the next step is making these tests widely available. Hospitals and health care systems across the country should ensure primary care physicians are aware of these tests and understand how to use them. Public education campaigns can raise awareness with people who have concerns about cognitive impairment and their detection gives people meaningful choices, and most importantly it gives people time. Time to benefit from lifestyle changes, participate in groundbreaking clinical trials, and access treatments when they can make the greatest difference. Although facing a potential Alzheimer's diagnosis is daunting, waiting only limits a person's options. If you're concerned that you or a loved one might have signs of cognitive impairment, please don't stay in the dark. Blood biomarker tests offer real hope in a new era of Alzheimer's care. The sooner we embrace these advances, the more precious time we can preserve.
Newsweek
3 hours ago
- Newsweek
Dr Pepper Recall Issued After Sugar Mix Up in Thousands of Cans
A recall has been issued for thousands of cases of Dr Pepper Zero Sugar that were mislabeled and contained the full-sugar product, according to the U.S. Food and Drug Administration (FDA). The products were distributed to retailers in Florida, Georgia, and South Carolina. Newsweek contacted Keurig Dr Pepper, which owns the product in the United States, and PepsiCo, which bottled the beverages, for comment via email outside of regular working hours. Why It Matters This mislabeling poses potential health risks to consumers, particularly for individuals managing conditions like diabetes or those monitoring their sugar intake The FDA has issued a Class II risk classification for the recall, indicating that the consumption of the mislabeled products may cause temporary or medically reversible adverse health consequences. What To Know The FDA said the company-initiated recall affects 19,203 cases of Dr Pepper Zero Sugar 12-fluid ounce cans, sold in 12-pack and 24-pack cartons. The affected cans were produced at a Pepsi bottling facility in Jacksonville, Florida, which is licensed to manufacture Keurig Dr Pepper products, according to the FDA. The affected products have the product code XXXXRS05165, and a best-by date of February 16, 2026. The recall was initiated on May 23, 2025, and the FDA classified it as a Class II recall on June 5, 2025. A can of regular Dr Pepper contains 39 grams of sugar, while the Zero Sugar version has zero grams, but contains the artificial sweeteners aspartame and acesulfame potassium. There were 241 FDA food and beverage recalls in 2024, which was an increase of eight percent from the previous year, according to a report published by the nonprofit Public Interest Research Group. Undeclared allergens or ingredients was the single biggest cause for recalls that year. Last year, Dr Pepper tied with Pepsi to become the second most popular soda in the U.S. after Coca Cola, according to data from Beverage Digest. What Happens Next The FDA and Dr Pepper are working to ensure that all affected products are removed from store shelves promptly. Consumers in the affected states should remain vigilant and check their purchases to ensure they have not bought the mislabeled product.
Epoch Times
9 hours ago
- Epoch Times
Fusarium Graminearum: The Fungus Allegedly Smuggled by Chinese Researchers—and Its Risks
A fungus called Fusarium graminearum has made headlines after two Chinese researchers were charged by the FBI for allegedly smuggling it into the United States as a potential agroterrorism agent. But what exactly is this fungus—and what risks does it pose to U.S. agriculture and public health? A Common Cause of Crop Disease F. graminearum is a concerning fungus, as it can contribute to billions of dollars in agricultural losses, Gary Bergstrom, professor emeritus at Cornell University specializing in plant pathology, told The Epoch Times.
